FROM ACADEMIA TO THE BIOPHARMA C-SUITE
From Academia To The Biopharma C-Suite
Not everyone pursues the completion of a doctoral degree with the mindset of becoming a college professor. However, there are many who do. And while this tends to happen less so in the life science space when compared to that of other disciplines, it does still happen. As such, we thought an executive virtual roundtable topic of, “From Academia To The Biopharma C-Suite,” would enable us to learn from those taking a less traditional path to becoming a biopharmaceutical executive. In this executive virtual roundtable (EVR), perspectives are provided by Rahul Aras, Ph.D., CEO, Iterion Therapeutics; Steffen Mueller, Ph.D., cofounder and CSO, Codagenix; and Prem Premsrirut, M.D., Ph.D., CEO, Mirimus.
FIRST-TIME CEOS: FIRSTHAND TALES OF THE GOOD, THE BAD, AND THE UGLY
First-Time CEOs: Firsthand Tales Of The Good, The Bad, And The Ugly
Since the CEO position comes with such high expectations and stress, we thought it would be interesting to speak with three first-time CEOs to hear their tales of the good, the bad, and the ugly. In this executive virtual roundtable (EVR), perspectives are provided by Roger Crystal, CEO, Opiant Pharmaceuticals; Frank Lee, CEO, Forma Therapeutics; and Ivana Magovcevic-Liebisch, Ph.D., J.D., CEO, Vigil Neuroscience.
TAKING A LIFE SCIENCE COMPANY PUBLIC DURING A PANDEMIC
Taking A Life Science Company Public During A Pandemic
If I said, “Biotech IPOs were hot last year,” it could be construed as one of the biggest understatements of all time. This is because in 2020, biotech IPOs shattered all records. Further, the positive biopharma IPO trend seems to be continuing for 2021, at least thus far anyway. As such, Life Science Leader thought it worthwhile to speak with three life science executives about their varied experiences of going public in the middle of a pandemic. Because while taking a company public may not be the dream of every entrepreneur, it is for many in life sciences, as the high cost of developing therapeutics remains.
MAKING DIVERSITY & INCLUSION A BEST BUSINESS PRACTICE
Making Diversity & Inclusion A Best Business Practice
Diversity and inclusion (D&I) is not to be confused with Affirmative Action, the law signed into being in the 1960s, as D&I is tied to an organization’s mission, strategies, and practices to support a diverse workplace, and seeks to leverage the effects of diversity to achieve a competitive advantage.
WHAT DOES IT TAKE TO START A BIOPHARMACEUTICAL COMPANY?
What Does It Take To Start A Biopharmaceutical Company?
As many Life Science Leader readers daydream of starting and leading their own biopharma company someday or leaving the comfort of Big Pharma or academia to join a startup, we thought it would be informative to host an executive virtual roundtable (EVR) with three company CEOs who have done just that. In this EVR, Faraz Ali, CEO, Tenaya Therapeutics; Rahul Ballal, Ph.D., CEO, Imara; and Sekar Kathiresan, M.D., CEO, Verve Therapeutics, share their startup journeys along with some best business practices and wisdom gained along the way.
PITCHING AND FUNDRAISING IN THE NEW NORM
Pitching And Fundraising In The New Norm
Raising money for a startup biopharma is a task that never ends, even during a pandemic. This is good. Because while some industries experienced significant financial collapse last year, biopharma was perfectly positioned to provide COVID-19 solutions, which it has at an unprecedented pace.
PREPARING FOR A VIRTUAL J.P. MORGAN HEALTHCARE CONFERENCE (JPM)
Preparing For A Virtual J.P. Morgan Healthcare Conference (JPM)
Unfortunately, like so many in-person events negatively impacted by COVID-19 last year, the 2021 JPM conference will be 100% virtual. So, we thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique JPM and how those preparations are different than what they’ve done in the past.
MANUFACTURING AND SUPPLY CHAIN RISK MITIGATION STRATEGIES AMIDST COVID-19
Manufacturing And Supply Chain Risk Mitigation Strategies Amidst COVID-19
Three biopharmaceutical industry executives to discuss some of the thinking and actions taken to mitigate risk to their companies’ manufacturing and supply chains amidst a pandemic.
TACKLING HR IN BIOPHARMA DURING A PANDEMIC
Tackling HR In Biopharma During A Pandemic
Three biopharma VPs of HR discuss the challenges of continued operations amidst COVID-19 initiated lockdowns, along with some of the best practices implemented.
ACCELERATING YOUR BIOPHARMA STARTUP'S PATH TO THE CLINIC
Accelerating Your Biopharma Startup’s Path To The Clinic
Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, and Dara Lockert, founder and executive director of Spannerwerks, a consultancy, share best practices and lessons learned during the drive to get a biopharma startup to the clinic as quickly as possible.
WHAT'S HAPPENING ON THE FRONT LINES OF COVID-19: A CEO ROUNDTABLE ON TECHNOLOGIES IN DEVELOPMENT FOR THE CURRENT PANDEMIC
What’s Happening On The Front Lines of COVID-19: A CEO Roundtable On Technologies In Development For The Current Pandemic
Four biopharma CEOs and cofounders discuss what their organizations are doing to spur the development of diagnostic tests, therapeutics, and vaccines to turn the tide on the COVID-19 pandemic.
LEADING THROUGH ADVERSITY: A CEO ROUNDTABLE ON DRUG DEVELOPMENT DURING A PANDEMIC
Leading Through Adversity: A CEO Roundtable On Drug Development During A Pandemic
Four biopharma CEOs discuss with Rob Wright, chief editor of Life Science Leader, how they are leading their organizations and conducting drug development during the COVID-19 pandemic.
PREPARING FOR THE NEW BIOMANUFACTURING FRONTIER: A FIRESIDE CHAT WITH FLUGEN'S ANDY SKIBO
Preparing For The New Biomanufacturing Frontier: A Fireside Chat With FluGen’s Andy Skibo
At the Generis 2020 American Biomanufacturing Summit (July 21 – 23), Andy Skibo, chief manufacturing officer for FluGen, discusses the challenges around developing and delivering a COVID-19 vaccine on a significantly shortened timeframe, plus other opportunities for improving biomanufacturing and its supply chain to support future therapies.
BIOPHARMA AND THE MANAGEMENT OF WALL ST. DURING A PANDEMIC
Biopharma And The Management Of Wall St. During A Pandemic
The volatility of the U.S. stock market in the first half of 2020 has even the heartiest investor queasy. But how about the leaders of such publicly traded companies? We conduct a virtual roundtable with three CEOs of publicly traded biopharmaceutical companies to learn how they are leading their organizations while also managing the expectations of Wall Street during the COVID-19 pandemic.
LEADERSHIP DURING COVID-19 — A BIOPHARMA CEO ROUNDTABLE
Leadership During COVID-19 — A Biopharma CEO Roundtable
Five biopharmaceutical industry CEOs discuss challenges their company's have faced, along with best practices implemented in managing through the COVID-19 chaos.
AN INTERVIEW WITH ROBERT HARIRI, M.D., PH.D., CEO AND FOUNDER OF CELULARITY
An Interview with Robert Hariri, M.D., Ph.D., CEO and founder of Celularity
A video of Life Science Leader chief editor, Rob Wright, interviewing Robert (Bob) Hariri, M.D., Ph.D., CEO and founder of Celularity, at the 2019 CNS Summit.
During the COVID-19 pandemic of 2020, Life Science Leader decided to engage with some of our executive-level readers via Zoom conference calls. These virtual roundtables were hosted by our Chief Editor Rob Wright and then broken up into shorter clips based on specific questions or topics discussed during the full-length call.